Sermorelin is the synthetic 29-residue N-terminal fragment of growth hormone-releasing hormone, written GHRH(1-29)-NH2 or GRF(1-29)-NH2. As a research material its value depends on knowing exactly what is in the vial: the correct sequence, the C-terminal amide, and how much of the material has already converted to closely related degradation products. This article covers the structure, the known chemical liabilities, and how those liabilities appear in the analytical data on a certificate. The material is for laboratory research use only; not for human consumption.
Sequence and structure
The one-letter sequence is YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2. The C-terminal arginine at position 29 carries a carboxamide rather than a free carboxylic acid. That difference changes the molecular mass and the charge behaviour, so the amidated form is the one that analytical data should be checked against. A free-acid analogue would differ in mass by roughly 1 Da, which is a reason to read the mass spectrometry section of a certificate closely.
Three positions account for most of the chemical instability: Asp3, Asn8 and Met27. The peptide also contains several basic residues (Arg and Lys at multiple positions plus the free N-terminus). As a result it ionises readily in positive-mode electrospray and appears as a series of multiply charged ions rather than a single singly charged species.
Formula, mass and charge states
The molecular formula, monoisotopic mass, average mass and the expected electrospray charge states should be taken from the certificate or the supplier's specification sheet for the material in hand, not recalculated from memory. When comparing data, confirm whether a quoted value is monoisotopic or average. For a peptide of this size the two differ appreciably, and mixing them up is a common source of apparent mismatches. Deconvoluted spectra are normally reported as a neutral mass, while raw spectra show m/z values for each charge state. Each observed m/z should be traceable back to the same neutral mass.
Degradation products in aqueous solution
Work on human growth hormone-releasing factor in aqueous solution identified deamidation at Asn8 and reactions at Asp3 as major routes of chemical degradation. Both processes depend strongly on pH (PMID: 1428526). Deamidation of Asn8 proceeds through a succinimide intermediate and yields two products: the [Asp8] form and the [beta-Asp8], or isoAsp8, form. Each is about 1 Da heavier than the parent, and the two products are isobaric with each other. A mass measurement alone can show that deamidation has occurred but cannot say which isomer is present.
At Asp3, the same body of work describes isomerisation and cleavage of the Asp3-Ala4 bond, giving the (4-29) fragment (PMID: 1428526). That fragment has a substantially lower mass than the parent and usually elutes as a distinct peak. Methionine oxidation is a separate, general liability of any Met-containing peptide. Oxidation of Met27 to the sulfoxide produces a species 16 Da heavier than the parent, typically promoted by dissolved oxygen, peroxide contaminants in solvents, or prolonged exposure to air and light.
Telling the species apart analytically
Because the deamidation products are isobaric with each other and only about 1 Da from the parent, separation does most of the work. Comparisons of separation and detection techniques for hGRF and its deamidation products showed that the Asp and isoAsp forms can be resolved from the parent and from each other under suitable conditions (PMID: 8357873). Mass spectrometry then confirms the mass shift for each resolved peak. Charge-state data help here: at higher charge states a 1 Da neutral shift becomes a fraction of an m/z unit, so the isotope envelope must be resolved before the shift can be assigned with confidence.
In practice, a deamidated impurity on reversed-phase HPLC appears as a separate, usually nearby peak. An oxidised impurity typically appears as an earlier-eluting peak because the sulfoxide is more polar, and its mass spectrum sits 16 Da above the parent. The (4-29) cleavage fragment appears with its own retention time and a clearly lower mass.
Reading the certificate
A certificate reports what one named third-party laboratory measured on one batch of material. It is identified by its Report ID or Laboratory ID, and for some batches results may still be pending. The reversed-phase HPLC section should show the chromatogram, the integration method and the main-peak retention time. Ideally it also shows a comparison against a reference standard run under the same conditions. Minor peaks near the main peak are worth noting against the degradation routes described above.
The mass spectrometry section should state both the observed and expected mass and indicate whether each value is monoisotopic or average. If a raw spectrum is included, the charge-state series should be consistent with a single neutral mass. Signals at roughly +1 Da or +16 Da relative to the parent, or a mass matching the (4-29) fragment, would point to deamidation, oxidation or cleavage respectively.
Bench handling and storage
Lyophilised powder should be kept cold, dry and protected from light. Before opening, let the vial reach room temperature so that condensation does not form on the solid. Solution stability is the main concern. The degradation literature places the region of greatest stability around pH 4-5, with deamidation at Asn8 accelerating at neutral to basic pH (PMID: 1428526).
When preparing a stock solution for assay, use a mildly acidic, low-peroxide solvent or buffer. Keep the time in solution as short as the experiment allows, and divide the stock into single-use aliquots so that the material is not subjected to repeated freeze-thaw cycles. Degassed solvents and minimal headspace help limit Met27 oxidation. If a stock has been held for an extended period, running it again by HPLC and MS before use in an assay gives a direct check on whether any of the known degradation products have grown in.
For research use only. This guide covers bench handling of laboratory research materials. It does not describe an application, benefit, dose, route or outcome, and nothing in it is guidance for use in a person or an animal. Nothing sold by PepXtide has been evaluated by the FDA.
Where this applies on the site
The certificate library
Every published certificate, scanned as the laboratory issued it.
Quality control
The method, the laboratory, and the real spread of results.
Sermorelin
Named in this guide. Growth & Secretagogue.
GHK-Cu
Has a published certificate to read against this guide.
GLP-2 (Tirzepatide) 20mg
Has a published certificate to read against this guide.
Tesamorelin
Has a published certificate to read against this guide.